As of Dec 08
| +0.0164 / +1.84%|
The 2 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 1.25, with a high estimate of 1.50 and a low estimate of 1.00. The median estimate represents a +38.01% increase from the last price of 0.91.
The current consensus among 4 polled investment analysts is to Hold stock in Regulus Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.